Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA) has announced the award of inducement grants to three new employees under its 2024 Inducement Plan. The grants consist of time-based restricted stock units (RSUs) for 21,863 shares of common stock, which will vest in three equal installments on February 1 of 2026, 2027, and 2028. The vesting is contingent upon continued service with Intellia.
The awards were granted outside of Intellia's stockholder-approved equity incentive plans through the 2024 Inducement Plan, which was adopted by the board in June 2024. The compensation committee approved these grants as material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) ha annunciato l'assegnazione di premi di indennizzo a tre nuovi dipendenti nell'ambito del suo Piano di Indennizzo 2024. I premi consistono in unità azionarie a restrizione temporale (RSU) per 21.863 azioni di azioni ordinarie, che matureranno in tre rate uguali il 1° febbraio del 2026, 2027 e 2028. La maturazione è subordinata alla continua prestazione di servizio con Intellia.
Gli assegni sono stati concessi al di fuori dei piani di incentivazione azionaria approvati dagli azionisti di Intellia tramite il Piano di Indennizzo 2024, adottato dal consiglio a giugno 2024. Il comitato di compensazione ha approvato questi premi come incentivo materiale per l'occupazione, in conformità con Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) ha anunciado la concesión de premios de inducción a tres nuevos empleados bajo su Plan de Inducción 2024. Los premios consisten en unidades de acciones restringidas basadas en el tiempo (RSUs) por un total de 21,863 acciones de acciones ordinarias, que se otorgarán en tres cuotas iguales el 1 de febrero de 2026, 2027 y 2028. La concesión está sujeta a la continuación del servicio con Intellia.
Los premios fueron otorgados fuera de los planes de incentivos en acciones aprobados por los accionistas de Intellia a través del Plan de Inducción 2024, que fue adoptado por la junta en junio de 2024. El comité de compensación aprobó estos premios como un incentivo material para el empleo de acuerdo con Nasdaq Listing Rule 5635(c)(4).
인텔리아 테라퓨틱스 (NASDAQ:NTLA)는 2024년 유인 계획에 따라 세 명의 신규 직원을 위한 유인 보조금을 발표했습니다. 이 보조금은 21,863주의 보통주에 대한 시간 기반 제한 주식 유닛(RSU)으로 구성되며, 2026년, 2027년, 2028년 2월 1일에 세 번에 걸쳐 동일한 비율로 취득됩니다. 취득은 인텔리아와의 지속적인 서비스에 따라 달라집니다.
이 보상은 인텔리아의 주주 승인을 받은 주식 인센티브 계획 외부에서 2024년 유인 계획을 통해 제공되었습니다. 보상 위원회는 이 보조금을 Nasdaq Listing Rule 5635(c)(4)에 따라 고용에 대한 물질적 유인으로 승인했습니다.
Intellia Therapeutics (NASDAQ:NTLA) a annoncé l'octroi de subventions d'incitation à trois nouveaux employés dans le cadre de son Plan d'Incitation 2024. Les subventions se composent d'unités d'actions restreintes basées sur le temps (RSUs) pour 21,863 actions ordinaires, qui seront acquises en trois versements égaux le 1er février 2026, 2027 et 2028. L'acquisition est conditionnée à un service continu auprès d'Intellia.
Les récompenses ont été accordées en dehors des plans d'incitation en actions approuvés par les actionnaires d'Intellia par le biais du Plan d'Incitation 2024, qui a été adopté par le conseil en juin 2024. Le comité de rémunération a approuvé ces subventions comme incitation matérielle à l'emploi conformément à la Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) hat die Vergabe von Induktionszuschüssen an drei neue Mitarbeiter im Rahmen seines Induktionsplans 2024 angekündigt. Die Zuschüsse bestehen aus zeitbasierten, beschränkten Aktieneinheiten (RSUs) für 21.863 Aktien von Stammaktien, die in drei gleichen Raten am 1. Februar 2026, 2027 und 2028 übertragen werden. Die Übertragung hängt von der Fortsetzung des Dienstes bei Intellia ab.
Die Auszeichnungen wurden außerhalb der von den Aktionären genehmigten Aktienanreizpläne von Intellia über den Induktionsplan 2024 vergeben, der im Juni 2024 vom Vorstand verabschiedet wurde. Der Vergütungsausschuss genehmigte diese Zuschüsse als wesentlichen Anreiz für die Beschäftigung gemäß Nasdaq Listing Rule 5635(c)(4).
- Strategic hiring with equity incentives to attract talent
- Structured vesting schedule promotes long-term employee retention
- Potential shareholder dilution from 21,863 new shares
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2025, it awarded an inducement grant to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 21,863 shares of Intellia’s common stock, with one-third of such RSUs vesting on February 1, 2026, 2027 and 2028.
All equity vesting is subject to the employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
The above-described award was granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. The award was approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com
This press release was published by a CLEAR® Verified individual.
FAQ
How many shares were granted in Intellia's (NTLA) February 2025 inducement grants?
What is the vesting schedule for NTLA's February 2025 inducement grants?
Under which plan were NTLA's February 2025 inducement grants awarded?
What Nasdaq rule governs NTLA's February 2025 inducement grants?
